BCLS II Investco, LP - Nov 5, 2025 SCHEDULE 13D/A Report for NewAmsterdam Pharma Company N.V. Ordinary Shares, nominal value Euro 0.12 per share (NAMS)

Filing Manager
BCLS II Investco, LP
Reporting Manager
BCLS Fund III Investments, LP
Security
NewAmsterdam Pharma Company N.V. Ordinary Shares, nominal value Euro 0.12 per share
Symbol
NAMS
Shares outstanding
114M shares
Disclosed Ownership
11.4M shares
Ownership
9.99%
Form type
SCHEDULE 13D/A
Date filed
11/7/2025, 07:19 PM
Date of event
Nov 5, 2025
Next filing
Dec 4, 2025
SEC
View on sec.gov

Reporting Managers (6)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
BCLS Fund III Investments, LP 9.99% 11.4M 0 11.4M /s/ Adam Koppel Adam Koppel, Partner of Bain Capital Life Sciences Investors, LLC 0001952107
Bain Capital Life Sciences Opportunities III, LP 9.99% 11.4M 0 11.4M /s/ Adam Koppel Adam Koppel, Partner of Bain Capital Life Sciences Investors, LLC 0001950105
Bain Capital Life Sciences Fund II, L.P. 9.99% 11.4M 0 11.4M /s/ Adam Koppel Adam Koppel, Partner of Bain Capital Life Sciences Investors, LLC 0001773187
BCLS II Investco, LP 9.99% 11.4M 0 11.4M /s/ Adam Koppel Adam Koppel, Partner of Bain Capital Life Sciences Investors, LLC 0001818893
BCLS II Equity Opportunities, LP 9.99% 11.4M 0 11.4M /s/ Adam Koppel Adam Koppel, Partner of Bain Capital Life Sciences Investors, LLC 0001814474
BCIP Life Sciences Associates, LP 9.99% 11.4M 0 11.4M /s/ Adam Koppel Adam Koppel, Authorized Signatory of Boylston Coinvestors, LLC 0001702921